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ABSTRACT
Objectives: The aim of this study was to determine the diagnostic value of 
diffusion-weighted MRI of the liver at 3T to classify liver fibrosis/cirrhosis.
Methods: 62 patients who underwent both histopathological examination and 
diffusion-weighted imaging of the liver via 3T MRI within a period of 3 months were 
included in the study. The Ishak score (1-6) was used to determine the degree of 
fibrosis: No liver fibrosis (NLF; Ishak 0, n = 16), mild liver fibrosis (MLF; Ishak 1-2, n 
= 23), advanced liver fibrosis (ALF; Ishak 3-5, n = 12), and liver cirrhosis (LC; Ishak 
6, n = 11).
Results: The corresponding ADC values for the individual patient groups were 
as follows: NLF: 1123 (SD 95.8); MLF: 1032 (SD 77.6); ALF: 962 (SD 68.8); LC: 1015 
(SD 60.2) mm2/s. There is a significant difference between NLF and MLF (p = 0.004) 
and between MLF and ALF (p = 0.022). A significant difference between patients with 
ALF and LC (p = 0.117) could not be found.
Conclusion: Liver fibrosis/cirrhosis lowers the ADC values of the liver parenchyma 
in 3T MRI. However, the degree of fibrosis can only be conditionally determined on 
the basis of ADC values.
INTRODUCTION
Liver cirrhosis is the irreversible end stage of liver 
fibrosis. It is characterized by destruction of the lobular 
and vascular architecture and nodular regeneration of 
liver tissue. Fibrosis of liver tissue results in extracellular 
accumulation of collagen fibers, proteoglycans, and other 
macromolecules [1]. The progression of liver fibrosis and 
the development of liver cirrhosis are currently viewed 
as a dynamic process: With adequate treatment of the 
primary disease, partial remission of liver fibrosis can 
even be achieved [2–4]. Tests showing restriction of the 
liver function early, allow for an adjustment of patient 
treatment, resulting in slowing or regression of the 
dynamic fibrosis process.
Liver biopsy is currently the gold standard in 
clinical practice for detecting and staging liver fibrosis/
cirrhosis. However, liver biopsy, as an invasive method, 
has poor patient acceptance, is susceptible to sampling 
errors, is subject to interobserver variability, and bears a 
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risk of complications, such as infection and bleeding [5]. 
The absence of characteristic fibrotic septae and nodular 
configurations can complicate the histological diagnosis of 
liver fibrosis/cirrhosis [6]. Moreover, sampling errors can 
underestimate the severity of the disease [7, 8].
With regard to the image-based diagnosis of 
fibrosis, abdominal ultrasound should be mentioned in 
particular. Ultrasound elastography (US-RTE) can be 
used to measure liver stiffness, thus allowing an indirect 
assessment of the degree of liver fibrosis [9, 10]. However, 
the diagnostic value of US-RTE is restricted here by the 
limited reproducibility and the examiner dependence of 
the method [11].
In addition to ultrasound imaging, MRI of the 
liver currently represents the gold standard of diagnostic 
methods. Recently published studies showed that liver 
fibrosis/cirrhosis can be characterized by liver MRI using 
a hepatospecific MR contrast agent [12–15].
Individual studies examined the possibility of using 
diffusion-weighted MRI examination at 1.5T for the 
classification of fibrosis [16–19]. We are currently not 
aware of any study examining the correlation of DWI and 
ADC values on a 3-Tesla MRI unit with histology.
RESULTS
In total, 62 patients were included in this 
retrospective study. 16 patients did not show any fibrotic 
remodeling of the liver parenchyma. 46 patients had a 
liver parenchyma with fibrotic/cirrhotic remodeling. Table 
1 shows the distribution of patients according to Ishak 
score with the corresponding ADC values.
There was a significant difference in the mean 
ADC value between patients without liver fibrosis (ADC 
= 1123 ± 95.8 mm2/s) and patients with any stage of liver 
fibrosis/cirrhosis (ADC = 1010 ± 76.13 mm2/s; p < 0.001) 
(Figure 1).
The corresponding ADC values for the individual 
patient groups were as follows: NLF: 1123 (SD 95.8); 
MLF: 1032 (SD 77.6); ALF: 962 (SD 68.8); LC: 1015 
(SD 60.2) mm2/s (Figure 2). In an adjusted pair-wise 
comparison (Table 2) a significant difference between 
patients without liver fibrosis and with mild liver fibrosis 
(p = 0.036) and between patients with advanced liver 
fibrosis (p ≤ 0,001) could be observed. No significant 
difference could be found between the different stages of 
liver fibrosis/cirrhosis ( p > 0.214) or between patients 
with without liver fibrosis and patients with liver cirrhosis 
(p = 0.053).
The ROC analysis (Figure 3, Table 3) showed 
significant cut-off values for the differentiation of Ishak 
≥ 1 and Ishak ≥ 3. In the case of an ADC value of 1034, 
patients without liver fibrosis could be differentiated 
from patients with liver fibrosis/cirrhosis ≥ Ishak 1 with a 
sensitivity of 87.5% and a specificity of 69.5%.
DISCUSSION
The present study was able to show that liver fibrosis 
affects the mean ADC value of the liver parenchyma. 
However, it was not possible to differentiate the individual 
degrees of fibrosis based on the present data.
There is a controversial discussion in the literature 
regarding the extent to which DWI can be used to 
differentiate between liver fibrosis and cirrhosis. It has 
been described that ADC values are significantly lower 
in patients with liver fibrosis/cirrhosis. Sandrasegaran 
et al., Taouli et al. and Ayse et al. reported a significant 
difference in ADC values for different stages of liver 
fibrosis/cirrhosis [16, 20, 21]. In contrast, studies by 
Boulanger et al. and Soylu et al. were not able to find 
a correlation between fibrosis stages and ADC values 
[17, 22].
As already described, the ADC values of the liver 
parenchyma were lower in 3T MRI in the case of liver 
fibrosis/cirrhosis in our study. The individual histological 
stages of liver fibrosis according to Ishak could not be 
differentiated from one another on the basis of ADC. 
However, there was a relevant difference between patients 
NLF and patients with any stage of liver fibrosis/cirrhosis 
(MLF + SLF + LC), but this significant difference is 
mainly effected by the NLF and MLF subgroup, as no 
significant difference between NLF and LC was observed.
Diffusion-weighted imaging is an MRI method 
that can also be used for detecting inflammatory/tumoral 
diseases in the abdomen [23, 24].
Liver fibrosis is characterized by destruction 
of the lobular and vascular architecture and nodular 
regeneration of liver tissue. Fibrosis of liver tissue 
results in extracellular accumulation of collagen fibers, 
proteoglycans, and other macromolecules [1]. In case 
of early stage fibrosis, Lee at al. reported that liver 
parenchyma is often edematous cased by new vessels have 
leaky interendothelial junctions, resulting in an increased 
portion of proteins and red blood cells in the extravascular 
space [25]. This process results in an increased deposition 
of hepatic water content, hypercellularity and increased 
ratio of free bound water in the liver parenchyma.
DWI measures the diffusion of water molecules 
in biological tissues and quantifies the water diffusion 
processes with the diffusion quotients ADC [26–28]. 
Theoretically, extracellular collagen fibers, glycosamine, 
and proteoglycans could inhibit the molecular diffusion 
of water and thus result in lower diffusion in case of liver 
fibrosis, especially in early stages [26, 28–30]. In case of 
liver cirrhosis, these effects might not be as dominant as 
in case of early-stage liver fibrosis, explaining the lack of 
significance for patients without liver fibrosis and patients 
with liver cirrhosis.
The loss of statistical significance regarding the 
individual degrees of fibrosis based on ADC at 3T is due 
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Table 1: ADC values categorized according to Ishak group
Ishak  N Description Mean ADC ± SD
0 NLF 16 No fibrosis 1123 ± 95.8
1 MLF 12 Fibrosis expansion of some portal areas ± short fibrous septa 1020 ± 77.8
2  7 Fibrosis expansion of most portal areas ± short fibrous septa 1024 ± 52.2
3 ALF 4 Fibrosis expansion of most portal areas with occasional portal to portal (P-P) bridging 1085 ± 109.6
4  7 Fibrosis expansion of portal areas with marked portal to portal (P-P) bridging as well as portal to central (P-C) 959 ± 68.7
5  5 Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) 965 ± 76.9
6 LC 11 Cirrhosis, probable or definite 1015 ± 60.2
Table 1 shows the corresponding ADC values with their standard deviations categorized on the basis of the individual Ishak 
values and the defined groups. NLF: no fibrosis, MLF: mild liver fibrosis, ALF: advanced liver fibrosis, LC: liver cirrhosis.
Figure 1: Images comparing the ADC-Maps with corresponding histopathology images with the EVG staining. Figure 
1 compares the ADC-Maps with corresponding histopathology from a patient with normal liver parenchyma (A) and from patient with end 
stage liver fibrosis (B). All images are with the same window level and center. The ADC-value of the liver parenchyma were as follows: 
(A) no liver fibrosis (Ishak 0), ADC: 859 mm2/s (B) advanced liver fibrosis (Ishak 5), ADC: 1128 mm2/s.
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to the inherent lowering of ADC values at 3T compared 
to 1.5T. Therefore, the working group of Rosenkrantz et 
al. described a shortened ADC time for the liver at 3T 
compared to 1.5T [31]. The influence of the shortened 
ADC time may explain the fact that the difference between 
the individual stages of fibrosis in a 3T system is too small 
for significant differentiation.
Our study has several limitations. First, this 
study has only a small study population so that the 
different influencing factors may not have been able to 
be fully discovered. Second, histological data from both 
liver biopsies and resections was used. As a result of 
differences in material quality, there could theoretically be 
discrepancies in the histological diagnosis. In particular, 
it can be difficult to differentiate between the individual 
degrees of liver fibrosis on the basis of liver biopsies.
In conclusion, the degree of liver fibrosis affects 
DWI particularly in early stage of liver fibrosis, but 
the corresponding degree of liver fibrosis cannot be 
determined based on the ADC value.
Figure 2: ADC values and liver fibrosis stage. Figure 2 shows box plots of the ADC values distributed according to the different 
fibrosis/cirrhosis groups. The mean ADC ± Standadart diviation values were as follows: no fibrosis, NLF: 1123 ± 95.8; mild liver fibrosis, 
MLF: 1032 ± 77.6; advanced liver fibrosis, ALF: 962 ± 68.8; liver cirrhosis, LC: 1015 ± 60.2 mm2/s.
Figure 3: ROC analysis. The graphs show the ROC curves with the corresponding sensitivity and specificity levels of the ADC values 
for the patient diagnoses (A) (Ishak ≥ 1; cut-off: 1034), (B) (Ishak ≥ 3; cut-off: 1016) and (C) (Ishak ≥ 4; cut-off: 1048).
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MATERIALS AND METHODS
Patients
In total, 62 patients were included in this 
retrospective analysis. All patients underwent MR 
imaging of the liver, either for the purpose of diagnosing 
suspicious liver lesions or as part of the monitoring of 
known liver cirrhosis. None of the recruited patients had a 
contraindication for MRI examination (e.g. claustrophobia, 
ferromagnetic foreign material, or pacemaker). Only 
patients who had undergone histopathological examination 
of the liver parenchyma in a period of 3 months were 
included in our study.
Imaging
All examinations were performed on a clinical 
3-Tesla system (Magnetom Skyra, Siemens Healthcare). 
A combination of body and spine coils (18-channel coil, 
body coil, 24-channel spine coil) was used for signal 
detection.
To calculate the ADC maps, breath-triggered spin 
echo EPI sequences for three B-values (50, 400, 800 s/
mm2) were used with adaptation to body weight using an 
S (small) and an L (large) program. (S: TR: 5700ms; TE: 
52ms; voxel size reconstructed: 1.98 x 1.98 x 6mm; voxel 
size measured: 2.38 x 1.98 x 6mm; L: TR: 5900ms; TE: 
52ms; voxel size reconstructed: 2.08 x 1.08 x 6mm; voxel 
size measured: 2.51 x 2.08 x 6mm; parallel imaging with 
an acceleration factor PAT2; averaging performed twice).
Sequence analysis
To calculate the average ADC time, three circular 
regions of interest (ROIs) were positioned in the liver. 
Special attention was paid to prohibit visible vessels, 
liver lesions, or regions with artifacts. The size of the ROI 
varied between 1 and 3.5 cm2. The thus measured average 
ADC was viewed as representative for the entire liver.
Histopathological analyses
Liver biopsies (27), as well as liver resections (35), 
were included in this study. Liver biopsies were performed 
as part of active patient monitoring in the case of known 
liver cirrhosis or an unclear liver tumor. Histological 
confirmation via surgery was obtained as part of either a 
liver transplantation or metastasis/liver tumor resection.
All tissue samples were fixed in neutral buffered 
formalin and embedded in paraffin. Histological slides 
with a thickness of 4 μm were prepared, deparaffinized 
with ethanol and xylene, and then stained according to the 
standard protocols for HE and EVG (Elastica van Gieson). 
The EVG staining was used to evaluate liver fibrosis. 
Collagen fibers turn red, while hepatocytes turn yellow.
Needle biopsy was used for the liver biopsy. The 
length of each biopsy specimen was measured and the 
Table 3: Sensitivity and Specificity of ROC-Analysis
 Ishak ≥ 1 Ishak ≥ 3 Ishak = 6
ADC cut-off 1034 1016 1048
Sensitivity (%) 87.5 68.6 64.7
Specificity (%) 69.6 63.0 45.5
AUC (95% CI) 82.6 (71.0, 94.2) 69.0 (55.7, 82.4) 43.1 (25.2, 61.1)
p-value p ≤ 0.001 p = 0.002 p = 0.478
Table 3 show the corresponding sensitivity and specificity levels of the ADC values for the patient diagnoses Ishak ≥ 1 (cut-
off: 1034), Ishak ≥ 3 (cut-off: 1016) and Ishak ≥ 4 (cut-off: 1048).
Table 2: Adjusted pair-wise comparison
 NLF MLF SLF LC
NLF  ≤ 0.001 0.036 0.053
MLF ≤ 0.001  0.214 0.838
SLF 0.036 0.214  1.000
LC 0.053 0.838 1.000  
Table 2 shows the corresponding p-values between the defined groups. NLF: no fibrosis, MLF: mild liver fibrosis, ALF: 
advanced liver fibrosis, LC: liver cirrhosis.
Oncotarget20117www.oncotarget.com
number of portal areas was counted. Only liver biopsies 
with a tissue length of at least 15 mm and 10 portal areas 
were used. Non-tumorous liver biopsies were exclusively 
included in the study. Two pathologists specialized in 
hepatopathology analyzed the liver specimens with 
respect to the degree of fibrosis. Both examiners were 
blinded to the radiological data and patient data. Their 
evaluations were performed independently. In the case of 
disagreement, scoring was performed again in consensus. 
The degree of liver fibrosis was determined according to 
the Ishak scoring system [1].
Statistical analysis
Statistical analysis was performed using IBM SPSS 
Statistics (Version 23, Chicago, IL). All data are specified 
as average ± standard deviation if not otherwise specified. 
A simple linear regression analysis was performed to 
correlate the degree of fibrosis/cirrhosis with the DWI 
data. For the pairwise comparison, the patients were 
divided into groups on the basis of histological data. 
To compare the DWI data of subgroups, an Analysis of 
Variance (ANOVA) followed by Bonferroni adjusted 
pairwise comparisons was calculated. All statistical 
analyses were two-sided and a p-value < 0.05 indicated a 
significant result.
Key points
Liver fibrosis/cirrhosis affects DWI at 3T.
With increasing liver fibrosis the ADC-Value is 
lowered.
ADC-Values can partly determined the degree of 
fibrosis.
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